Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 38,000 shares, a growth of 49.6% from the November 30th total of 25,400 shares. Currently, 0.8% of the company's stock are sold short. Based on an average trading volume of 8,400 shares, the days-to-cover ratio is presently 4.5 days.
Anebulo Pharmaceuticals Stock Down 6.8 %
ANEB stock opened at $2.42 on Friday. The firm has a 50 day moving average of $2.62 and a two-hundred day moving average of $3.17. Anebulo Pharmaceuticals has a 12 month low of $1.77 and a 12 month high of $7.89. The company has a market capitalization of $62.13 million, a price-to-earnings ratio of -7.13 and a beta of -1.48.
Get Anebulo Pharmaceuticals alerts:Anebulo Pharmaceuticals (NASDAQ:ANEB – Get Rating) last issued its quarterly earnings data on Thursday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter. On average, research analysts expect that Anebulo Pharmaceuticals will post -0.5 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. LVW Advisors LLC bought a new position in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB – Get Rating) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 700,000 shares of the company's stock, valued at approximately $3,640,000. LVW Advisors LLC owned 3.00% of Anebulo Pharmaceuticals as of its most recent SEC filing. 26.70% of the stock is currently owned by institutional investors and hedge funds.Anebulo Pharmaceuticals Company Profile
(Get Rating)
Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.
Featured Articles
- Get a free copy of the StockNews.com research report on Anebulo Pharmaceuticals (ANEB)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.